HOME >> MEDICINE >> NEWS
Interferons for treatment of SARS?

Authors of a research letter in this week's issue of THE LANCET suggest that recombinant interferons - synthetic versions of naturally occurring compounds of the immune system - could be a an effective treatment for Severe Acute Respiratory Syndrome (SARS).

Although antivirals are probably essential for the treatment of SARS-CoV infection, the antiviral ribavirin (a conventional treatment for SARS) is not always effective. Jindrich Cinatl from Frankfurt University Medical School, Germany, and colleagues assessed the antiviral potential of recombinant interferons against two strains of the SARS coronavirus (SARS-CoV) analysed in Frankfurt and Hong Kong. The investigators replicated the virus in two cell lines in a laboratory setting.

Interferon beta was effective in the two cell lines; interferon alpha effectively inhibited SARS-CoV replication, but with a sensitivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in one of the cell lines, but was completely ineffective in the other cell line.

Jindrich Cinatl comments: "We showed that interferons inhibit SARS-CoV replication in vitro. Interferon beta was most potent, showing prophylactic protection and antiviral potential after infection. Interferon beta could be the drug of choice, alone or in combination with other antiviral drugs, in the treatment of SARS."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
24-Jul-2003


Page: 1

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Chronic pain treatments more effective when taken together, new study shows
3. Brain activity prior to treatment flags vulnerability to antidepressant side effects
4. Cultural and social factors influence prostate cancer treatment
5. Research offers hope of new treatments for liver damage
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Stanford patient is first to test new treatment for peripheral arterial disease
8. Scientist works on innovative treatments for brain tumors
9. Blacks less likely to get expensive, newer heart treatments
10. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
11. Study examines lessons learned at Africas first public antiretroviral treatment clinic

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... Aliso Viejo, CA (PRWEB) , ... April 29, 2016 , ... ... Cut Pro X. Utilize Pixel Film Studios’ lower thirds to introduce people, characters, and ... preset styles that include boxes, lines, accents, textures and many more design components. Simply ...
(Date:4/29/2016)... ... April 29, 2016 , ... The number of chronically ... aging – meaning that there is an urgent need for highly skilled care managers ... solution, delivering a multi-pronged approach to train and retain care managers, and enhance their ...
(Date:4/29/2016)... ... 2016 , ... Orthodontics Limited, one of the nation’s top ... Middleberg, were asked by Invisalign to present an “Ask the Expert” ... “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. Gemmi and Dr. Middleberg demonstrated ...
(Date:4/28/2016)... ... April 29, 2016 , ... Sublime Beauty® is offering a special deal on its ... 50% off. The discount is applied to the product with lesser value. In addition, ... who purchase $250 or more in products. , "So many women (men, too) love our ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... on the world stage this week. A group of researchers and leaders from ... the Progress of Regenerative Medicine and Its Cultural Impact ” and receive the ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
Breaking Medicine Technology:
Cached News: